Bivalirudin Trifluoroacetate
Bivalirudin Trifluoroacetate is a direct thrombin inhibitor anticoagulant used primarily during percutaneous coronary intervention (PCI) procedures and in patients with unstable angina. It provides anticoagulation by reversibly binding to both free and clot-bound thrombin, preventing blood clot formation. This medication is administered intravenously under medical supervision in hospital settings.
Bivalirudin Trifluoroacetate is an intravenous anticoagulant used to prevent blood clots during heart procedures.
Key facts at a glance
- RxNorm
- 2380556
- Generic
- Bivalirudin Trifluoroacetate
- Class
- pin-variant
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 0.75 mg/kg bolus then 1.75 mg/kg/hr infusion
- Maximum
- consult physician
- Frequency
- continuous infusion
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.375 mg/kg bolus then 0.5 mg/kg/hr infusion
- Maximum
- consult physician
- Frequency
- continuous infusion
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.75 mg/kg bolus then 1.75 mg/kg/hr infusion adjusted for renal function
- Maximum
- consult physician
- Frequency
- continuous infusion
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
7 groupspregnancy
first trimesterno specific adjustment
use only if clearly needed and benefits outweigh potential risks
regular fetal monitoring and maternal bleeding assessment
Use with caution and monitor for adverse effects.
pregnancy
third trimesterno specific adjustment
use only if benefits outweigh risks due to potential bleeding risk near delivery
close maternal and fetal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingnot applicable
discontinue breastfeeding or pump and discard milk during treatment and for 24 hours after
monitor infant for bleeding signs
geriatric
elderlyno specific dose reduction but monitor closely
use with caution due to increased bleeding risk assess renal function
monitor renal function and for signs of bleeding
Use with caution and monitor for adverse effects.
pediatric_age
pediatricsnot established
use only in specialized pediatric centers under close supervision
intensive monitoring for bleeding and efficacy
renal_impairment
moderate to severereduce dose in severe renal impairment CrCl less than 30 mL/min
monitor activated partial thromboplastin time aPTT adjust dosing based on renal function
regular aPTT and renal function monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
hepaticno adjustment needed
no dose adjustment required as not significantly metabolized by liver
standard monitoring for bleeding
Statistics and clinical data
Drug class
Anticoagulant medication classification
FDA approved
Initial FDA approval year for bivalirudin
Primary indications
Main therapeutic indications
Mechanism of action
Molecular mechanism of anticoagulation
Used as an anticoagulant for patients undergoing percutaneous coronary intervention (PCI), including those with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and unstable angina. Also used as an alternative to heparin in patients at risk of heparin-induced thrombocytopenia.
A synthetic peptide that directly inhibits thrombin (Factor IIa) by reversibly binding to both the active site and exosite 1 of the thrombin molecule, thereby preventing conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet aggregation.
Administered intravenously with dosing based on weight and renal function. Requires careful monitoring of activated clotting time (ACT) during procedures. Contraindicated in patients with active major bleeding or hypersensitivity. May increase bleeding risk and should be used with caution in patients with renal impairment. Reversible action allows for predictable recovery of coagulation.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy